Stifel analyst Paul Matteis raised the firm’s price target on Alnylam (ALNY) to $495 from $441 and keeps a Buy rating on the shares. After an “outstanding first quarter” for Alnylam’s Vutrisiran, which the firm believes is on track to “beat numbers” handily in the near term, the firm is updating its TTR market model, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY: